CTOs on the Move

New York Cancer and Blood Specialists

www.nycancer.com

 
New York Cancer & Blood Specialists is committed to our patients. We are dedicated to providing each patient with a unique path to treatment and unmatched support. We strive to make quality, comprehensive cancer care available to each and every patient throughout New York.
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million
  • www.nycancer.com
  • 1500 Route 112 Building 4
    Port Jefferson Station, NY USA 11776
  • Phone: 631.751.3000

Executives

Name Title Contact Details
Carlos Ng
Vice President of Information Technology Profile
Sean Riley
Chief Information Officer Profile

Similar Companies

Teva Animal Health

Teva Animal Health is a Saint Joseph, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Organon

At Organon, we envision a better and healthier every day for every woman. The diversity of our business provides a sustainable engine of growth so we can identify and invest in solutions for women. Our mission is to deliver impactful medicines and solutions for a healthier every day. We believe the journey to improve women`s health is critical to achieving a healthier world. We are united in our drive to better support the health of women within our company and around the globe. Together, we work toward our goal of finding solutions for the healthcare issues that matter most to her, today and every day.

TLC Laser Eye Centers

TLC Laser Eye Centers is North America’s leading laser eye surgery provider, with more than 20 years of LASIK experience. Book a Free Consultation near you.

Immuno Vaccine

Immuno Vaccine is a Halifax, NS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Innocrin Pharmaceuticals

Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.